LT3733712T - Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą - Google Patents

Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą

Info

Publication number
LT3733712T
LT3733712T LTEP20180938.1T LT20180938T LT3733712T LT 3733712 T LT3733712 T LT 3733712T LT 20180938 T LT20180938 T LT 20180938T LT 3733712 T LT3733712 T LT 3733712T
Authority
LT
Lithuania
Prior art keywords
ofatumumaba
schedules
routes
multiple sclerosis
sclerosis
Prior art date
Application number
LTEP20180938.1T
Other languages
English (en)
Inventor
Erik WALLSTRÖM
Marina SAVELIEVA PRAZ
Algirdas Jonas KAKARIEKA WEISSKOPF
Joseph Michael KAHN
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3733712T publication Critical patent/LT3733712T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP20180938.1T 2016-08-15 2017-08-11 Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą LT3733712T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15

Publications (1)

Publication Number Publication Date
LT3733712T true LT3733712T (lt) 2023-09-11

Family

ID=59901554

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17768863.7T LT3497132T (lt) 2016-08-15 2017-08-11 Išsėtinės sklerozės gydymo ofatumumabu režimai ir būdai
LTEP20180938.1T LT3733712T (lt) 2016-08-15 2017-08-11 Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP17768863.7T LT3497132T (lt) 2016-08-15 2017-08-11 Išsėtinės sklerozės gydymo ofatumumabu režimai ir būdai

Country Status (24)

Country Link
US (5) US11161909B2 (lt)
EP (5) EP3497132B1 (lt)
JP (2) JP6851391B2 (lt)
KR (2) KR20200136503A (lt)
CN (5) CN120000782A (lt)
AU (2) AU2017311664C1 (lt)
CA (2) CA3030530C (lt)
CY (1) CY1123350T1 (lt)
DE (1) DE202017007542U1 (lt)
DK (2) DK3497132T3 (lt)
ES (2) ES2954259T3 (lt)
FI (1) FI3733712T3 (lt)
HR (2) HRP20201388T1 (lt)
HU (2) HUE063625T2 (lt)
IL (4) IL276890B2 (lt)
LT (2) LT3497132T (lt)
MX (1) MX388593B (lt)
PL (2) PL3733712T3 (lt)
PT (2) PT3497132T (lt)
RS (2) RS64541B1 (lt)
RU (1) RU2749951C2 (lt)
SI (2) SI3497132T1 (lt)
TW (1) TWI752995B (lt)
WO (1) WO2018033841A1 (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64541B1 (sr) 2016-08-15 2023-09-29 Novartis Ag Režimi i postupci za lečenje multiple skleroze upotrebom ofatumumaba
AU2020347474A1 (en) * 2019-09-11 2022-04-07 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
CN114401742B (zh) 2019-09-11 2024-05-24 诺华股份有限公司 通过转换疗法治疗rms
BR112022019038A2 (pt) * 2020-04-09 2022-11-01 Novartis Ag Ofatumumab para tratamento de em enquanto mantém a igg sérica
US20240228647A1 (en) * 2021-04-14 2024-07-11 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US20020064823A1 (en) 2000-03-30 2002-05-30 Welcher Andrew A. CD20/IgE-receptor like molecules and uses thereof
EP1311530A4 (en) 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2012018704A1 (en) 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
JP2014506258A (ja) * 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用
CN104254544B (zh) * 2012-02-08 2017-04-26 Igm生物科学有限公司 Cdim结合蛋白及其用途
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
CN106699886A (zh) 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
RS64541B1 (sr) 2016-08-15 2023-09-29 Novartis Ag Režimi i postupci za lečenje multiple skleroze upotrebom ofatumumaba
AU2020347474A1 (en) 2019-09-11 2022-04-07 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
CN114401742B (zh) 2019-09-11 2024-05-24 诺华股份有限公司 通过转换疗法治疗rms
BR112022019038A2 (pt) 2020-04-09 2022-11-01 Novartis Ag Ofatumumab para tratamento de em enquanto mantém a igg sérica
US20240228647A1 (en) 2021-04-14 2024-07-11 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
IL310813A (en) 2021-08-16 2024-04-01 Novartis Ag OFATUMUMAB for the treatment of multiple sclerosis in children

Also Published As

Publication number Publication date
AU2017311664B2 (en) 2020-01-02
CA3101514A1 (en) 2018-02-22
PT3733712T (pt) 2023-08-31
IL276890B2 (en) 2023-10-01
JP2020100630A (ja) 2020-07-02
KR20190038914A (ko) 2019-04-09
EP4371611A2 (en) 2024-05-22
US20240317878A1 (en) 2024-09-26
CA3030530C (en) 2021-02-23
EP4252847A2 (en) 2023-10-04
MX2019001860A (es) 2019-07-08
DE202017007542U1 (de) 2022-07-19
CN120037367A (zh) 2025-05-27
TWI752995B (zh) 2022-01-21
IL276890B1 (en) 2023-06-01
RU2749951C2 (ru) 2021-06-21
MX388593B (es) 2025-03-20
RS60807B1 (sr) 2020-10-30
AU2020201112A1 (en) 2020-03-05
RU2019107146A3 (lt) 2020-09-15
LT3497132T (lt) 2020-10-12
US20190177424A1 (en) 2019-06-13
EP3497132A1 (en) 2019-06-19
US20220081488A1 (en) 2022-03-17
EP4711008A2 (en) 2026-03-18
RU2019107146A (ru) 2020-09-15
HRP20201388T1 (hr) 2020-11-27
JP6851391B2 (ja) 2021-03-31
IL302488B2 (en) 2024-12-01
IL276890A (en) 2020-10-29
CN120053638A (zh) 2025-05-30
JP2019511506A (ja) 2019-04-25
PT3497132T (pt) 2020-09-25
EP4252847A3 (en) 2023-11-15
IL302488B1 (en) 2024-08-01
SI3733712T1 (sl) 2023-12-29
AU2017311664C1 (en) 2025-05-22
TW201808333A (zh) 2018-03-16
CN120000782A (zh) 2025-05-16
CY1123350T1 (el) 2021-12-31
EP3733712A1 (en) 2020-11-04
US11161909B2 (en) 2021-11-02
RS64541B1 (sr) 2023-09-29
DK3497132T3 (da) 2020-09-07
HUE063625T2 (hu) 2024-01-28
FI3733712T3 (fi) 2023-08-22
US20250289902A1 (en) 2025-09-18
CA3030530A1 (en) 2018-02-22
CN109641965A (zh) 2019-04-16
RU2021105514A3 (lt) 2022-02-08
ES2821924T3 (es) 2021-04-28
PL3497132T3 (pl) 2020-11-30
WO2018033841A1 (en) 2018-02-22
AU2020201112B2 (en) 2021-07-22
EP3497132B1 (en) 2020-06-24
EP4371611A3 (en) 2024-07-24
US20240150485A1 (en) 2024-05-09
HRP20230894T1 (hr) 2023-11-24
RU2021105514A (ru) 2021-04-19
CN120053639A (zh) 2025-05-30
SI3497132T1 (sl) 2020-10-30
IL313932A (en) 2024-08-01
US12570754B2 (en) 2026-03-10
AU2017311664A1 (en) 2019-01-31
US12338290B2 (en) 2025-06-24
KR20200136503A (ko) 2020-12-07
IL264804B (en) 2020-09-30
HUE051948T2 (hu) 2021-03-29
ES2954259T3 (es) 2023-11-21
JP7198786B2 (ja) 2023-01-04
AU2020201112C1 (en) 2025-05-22
EP3733712B1 (en) 2023-05-24
DK3733712T3 (da) 2023-08-21
IL302488A (en) 2023-06-01
PL3733712T3 (pl) 2023-10-16

Similar Documents

Publication Publication Date Title
EP4745456A2 (en) OVERLAPPING FACETS
IL261442A (en) Tgfb1-binding immunoglobulins and use thereof
LT3347379T (lt) Anti-tigit antikūnai, anti-pvrig antikūnai ir jų kombinacijos
LT3448386T (lt) Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas
LT3443009T (lt) Anti-tim-3 antikūnai ir kompozicijos
LT3578547T (lt) Sulfonilkarbamidai ir giminingi junginiai bei jų panaudojimas
EP3430731A4 (en) IUGW ARCHITECTURE
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
KR20180085041A (ko) 칫솔
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3128005T (lt) Sirp-alfa varianto konstruktai, ir jų panaudojimas
EP3515503A4 (en) MODIFIED LYMPHOCYTES
KR102423233B9 (ko) 맞춤형 시설
LT3672948T (lt) Piridinamino-piridono ir pirimidinamino-piridono junginiai
EP3476198A4 (en) HARVESTER
LT3337506T (lt) Deriniai ir jų panaudojimas
EP3960158C0 (en) AMLODIPINE FORMULATIONS
EP3449912A4 (en) MELTING TABLET
EP3631309C0 (de) Luftwäscher
EP3504446C0 (en) FIXING ELEMENT
DK3469445T3 (da) Termoelektrisk generator
EP3732380C0 (en) FIXING PART
EP3424943A4 (en) PEPTIDE
EP3800199C0 (en) H3.3 CTL PEPTIDES AND THEIR USES
IT201700039351A1 (it) Miscela antimeristematica e antigermogliante